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Introduction have demonstrated an association between activation
of coagulation and PAOD. Furthermore, in 1988, Boneu
In addition to well-established risk factors such as showed that PAOD was associated with inhibition of
fibrinolysis.7 In young patients (<51 years old) under-smoking, diabetes, hypercholesterolaemia and hyper-
tension, an increasing number of novel humoral and going lower limb revascularisation, as many as 76%
may have a hypercoagulable state (increased plateletendothelial factors have recently been implicated in
the aetiology and progression of vascular disease. aggregation or coagulation abnormality).8
Thrombophilia may be defined as a propensity to
thrombosis secondary to abnormalities in hae-
mostasis.1 Thrombophilia has long been recognised as
contributing to venous thrombosis, but is increasingly Homocysteine
associated with arterial disease. It is important because
screening may identify patients at high risk of throm- A mild elevation of homocysteine levels (hyper-
bosis who may then be offered prophylaxis. This re- homocysteinaemia) affects 5% or more of the popu-
view will focus on the prevalence and significance of lation and is increasingly recognised as an independent
thrombophilic states associated with peripheral ar- risk factor for atherosclerosis and thrombosis.9 Hyper-
terial occlusive disease (PAOD) and discuss possible homocysteinaemia can cause increased Factor V ac-
strategies for screening and treatment. tivity, possibly via a decrease in thrombomodulin cell
surface activity and a corresponding decrease in ac-
tivated protein C (Fig. 1).10–13 The prevalence of hy-
perhomocysteinaemia in PAOD may be between 50Prevalence of Thrombophilia
and 60%14–16 and many cross-sectional studies have
demonstrated a clear association between plasmaGeneral coagulation activation
homocysteine levels and PAOD.17
If thrombophilia is important in PAOD then there
should be evidence of activation of coagulation in
affected patients. Thrombin and fibrinogen, and prod-
ucts of their metabolism, including thrombin-anti- Antithrombin III
thrombin (TAT) complexes, prothrombin fragments
(PF) 1+2 and fibrin degradation products (FDPs) can Anti-thrombin III (AT III) is an endogenous anti-co-
be used to measure coagulation activation. Cross- agulant, produced by the liver, which inactivates
sectional2–5 and longitudinal6 epidemiological studies thrombin and factor Xa. Deficiency of AT III is inherited
in an autosomal dominant fashion. In a population-
based study of 7983 subjects over 55 years old 3.1%∗ Please address all correspondence to: P. Burns, Birmingham Heart-
lands Hospital, Bordesley Green East, Birmingham B9 5SS. had deficiency of AT III, defined as <75% activity.18
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Cross-sectional studies have shown that the pre-
valence of aPL amongst patients with PAOD requiring
intervention varies between 26% and 45%.28–30 This
mostly comprises patients with aCL who constitute
84–94% the total. A small proportion of patients with
aPL have both LAC and aCL (2–3%).28,30,31 No studies
have yet compared the prevalence of aPL in PAOD
with the prevalence in the general population, and no
large cross-sectional studies have been performed to
give a population prevalence of aPL.
Protein C deficiency
Protein C is a vitamin K dependent protein which,
when activated by the thrombin-thrombomodulin
complex, inactivates factors Va and VIIIa (Fig. 1).
Protein C deficiency is established as a risk factor for
venous thrombosis, but its role in arterial pathologyFig. 1. Overview of coagulation system.
is less clear. Few studies have investigated the pre-
valence of protein C deficiency in PAOD. In a recent
study of 116 claudicants, deficiency of protein C wasFibrinogen
found in 2 (1.7%).31 Other studies have shown the
prevalence of protein C deficiency to be between 2.5Fibrinogen is the substrate on which the end-product
and 15% in PAOD patients, but no comparisons wereof the coagulation cascade, thrombin, acts to produce
made with control groups.8,32–34fibrin, and ultimately, a blood clot. Its effects are
diverse and include increases in blood viscosity, red
cell aggregation, platelet aggregation and activation.19
Fibrinogen deposited in the arterial intima may also
Activated protein C resistance/factor V Leidenlead to smooth muscle cell proliferation and leukocyte
migration.20–23 Hyperfibrinogenaemia has long been
Activated protein C (APC) resistance is the most com-associated with cardiovascular disease and is present
mon inherited risk factor for thrombosis. The pre-in more than 50% of patients with PAOD.24–26
valence varies in different ethnic populations; in U.K.
it is 3.5–4.9%, Africans 0% and in Cyprus 13%.35,36 The
most common cause of APC resistance is a mutation
in the factor V gene leading to the replacement ofAntiphospholipid antibodies
Arginine 506 with Glutamine, (factor V Leiden, fVL)
which renders it more resistant to degradation byAntiphospholipid antibodies (aPL) are a group of auto
antibodies originally thought to be targeted towards protein C. This is responsible for 90–95% of APC
resistance, the remainder of which is made up ofnegatively charged phospholipid, although recent
work suggests that they are directed against 2-gly- acquired conditions such as aPL, pregnancy and the
oral contraceptive pill.37–40 APC resistance is measuredcoprotein I.27 aPLs are of two types, detected by dif-
ferent laboratory methods: the anticardiolipin using a plasma assay and exogenous activated protein
C, and is indicated by a lowering of the APC ratioantibody (aCL) enzyme linked immunoassay and the
lupus anticoagulant (LAC) coagulation assay. Al- (normal range 2.2 to 2.6). This will identify the majority,
but not all of patients with fVL. fVL may also bethough the lupus assay relies on the in-vitro effect of
aPL to prolong coagulation assays, the in-vivo effect is identified directly using genomic analysis, but not all
mutations lead to lowering of the APC ratio. fVL isprocoagulant, the mechanism for which is uncertain.
Antiphospholipid antibodies may inhibit protein C thought to underlie 18–30% of venous thromboses, but
its importance in arterial disease is less well defined.and protein S, and have prothrombotic effects via
enhanced platelet reactivity or endothelial cell surface Both APC resistance and fVL have been dem-
onstrated to be more common in patients with PAODmolecules such as heparan sulphate and tissue factor.27
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compared with the general population. Sampram prevalence of thrombophilic states in PAOD, perhaps
as high as 60%. Although common, the clinical rel-found the prevalence of fVL and APC resistance (de-
fined as ratio <2.6) to be higher (26.4%) in 359 patients evance of thrombophilia in PAOD is a more important
issue, which will now be discussed.with PAOD than in 278 controls (12.2%).41 A smaller
study by Foley in patients who had undergone lower
limb arterial bypass surgery reported a 17.8% pre-
Significance of Thrombophiliavalence of fVL, compared with a local population
prevalence of 3.5%.35 Evans only reported one positive
Studies of general coagulation activationAPC resistant patient in 116 claudicants.31 Variations
in these reported figures may be explained by the
There is a correlation between the level of coagulationpreferential use of DNA analysis or APC ratio to define
activation and the severity of PAOD as determinedfVL; variations in the lower end of the normal range
by walking distance,4 ankle–brachial pressure indexfor defining the normal APC ratio and the severity of
(ABPI),47,48 duplex ultrasonography, angiography49 andthe presenting PAOD.
clinical symptoms.25 For example, Ray reported the
prevalence of thrombophilia (protein C deficiency,
protein S deficiency, antithrombin III deficiency, lupus
anticoagulant) to be 11% in controls, 27% in claudicantsProtein S deficiency
and 40% in patients who had received a re-
vascularisation.34Protein S is a vitamin K dependent plasma protein
The importance of a hypercoagulable state in PAODand an essential co-factor for the anticoagulant and
has also been revealed through the association betweenprofibrinolytic effect of activated protein C.42 Protein
coagulation abnormalities and the progression ofS deficiency has been identified as a cause of venous
PAOD. In the Edinburgh Artery Study, whole bloodthrombosis, and more recently has been proposed as
viscosity, plasma viscosity and fibrinogen levels werea factor in arterial disease. The prevalence of protein
predictive of the requirement for vascular interven-S deficiency in the general population is thought to
tion,50 or fall in ABPI,6 over a six-year follow-up period.be around 0.7%.43 There are only a few small studies
Furthermore, whole blood viscosity, and fibrinogeninvestigating the prevalence of protein S deficiency in
levels have been shown to be predictive for the pro-PAOD. Allart in 1990 showed protein S deficiency to
gression of PAOD as determined by walking distance.51be present in 3 out of 45 patients (8%) less than 45
Thrombophilic states may also be important causesyears old who required surgical treatment for PAOD.42
of failure of arterial interventions. In 1994, Ray studiedA study of 33 patients undergoing arterial surgery,
124 patients undergoing arterial reconstruction andand 10 controls found a prevalence of protein S de-
reported 75 graft occlusions after a mean follow up officiency in PAOD patients of 15%. Although no stat-
44 months.34 Almost half (49%) of these were sub-istical difference was shown between patients and
sequently identified as having a thrombophilia, com-healthy controls, all five subjects with protein S levels
pared with 27% of patent reconstructions.less than normal were PAOD patients.44
Abnormalities identified in the graft occlusion group
were: protein C deficiency (21% of occlusions), protein
S deficiency (17%), lupus anticoagulant (25%) and
multiple abnormalities (12%). A subsequent pro-Prothrombin 20210A
spective study, investigated the presence of a throm-
bophilia prior to arterial reconstruction in 60 patientsA G to A transition at position 20210A of the pro-
thrombin gene is associated with an increased risk of with one-year follow-up.52 A pre-operative throm-
bophilia was identified in 65% of patients whose graftvenous thrombosis, although the underlying mech-
anism is not clear. The prevalence of this mutation is subsequently occluded within one year, compared
with 20% of those with a patent graft (p<0.05). The1.2% to 4.3% in patients with venous thrombosis,
5.7% in patients with PAOD, and 0.7% in controls.45,46 presence of thrombophilia was particularly significant
in early graft failures, where 11 of the 12 occlusionsHowever, no specific studies have been performed
investigating the association between prothrombin within one month had a pre-operative hyper-
coagulable abnormality. A prospective study of 13720210A and arterial disease.
Despite studies screening for different states, using patients undergoing a mixture of arterial re-
constructions identified 14 patients (10%) with a hy-a variety of methods, in patients with a range of
disease severity, it is clear that there is an increased percoagulable state.33 Three of these patients (27%)
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suffered a graft thrombosis within 30 days, compared and patency following percutaneous angioplasty are
with two of 123 patients with a normal thrombophilia conflicting. Two prospective studies have shown that
screen (1.6%). Eldrup Jorgensen studied 20 young (<51 hyperfibrinogenaemia is associated with poorer pat-
years old) patients undergoing aorto-iliac (7) or infra- ency rates, while another prospective study showed
inguinal (13) vascular surgery.8 Four patients suffered that high fibrinogen levels measured prior to an-
an early (<30 days) post-operative thrombosis, all of gioplasty were associated with improved patency
who had thrombophilia identified pre-operatively. rates.64–66
Patients with multiple coagulation abnormalities ap- At present there are no selective treatments available
pear to be at special risk. Thus, of 124 patients under- to lower fibrinogen and consequently no reported trials
going revascularisation studied by Ray, 11 had confirming benefit in treating hyperfibrinogenaemia.
multiple thrombophilias, all of whom had had a pre- While there is a great deal of evidence associating
vious revascularisation. Nine of these patients had a fibrinogen levels and PAOD, it is difficult to conclude
further occlusion during the follow-up period.34 that this relationship is causal until such trials are
available. Fibrinogen is an acute phase protein, and
its increased levels in arterial disease may merely be
representative of an underlying low-grade in-
Homocysteine flammatory process.
Hyperhomocysteinaemic patients have an increased
rate of vein graft stenosis and increased failure of
bypass grafts and angioplasty.16,53 Patients undergoing
peripheral arterial bypass surgery with elevated homo-
Antiphospholipid antibodiescysteine have evidence of pre-existing intimal hy-
perplasia in saphenous vein biopsies.15 A prospective
No studies to date have demonstrated an associationstudy investigating hyperhomocysteinaemia and pro-
between the prevalence of aPL and the progressiongression of PAOD, with mean follow-up of 37 months
of PAOD. However, aPL and the antiphospholipidfound a trend towards an association, but this was
syndrome are associated with an increased risk ofnot statistically significant.54 This may, however, rep-
thrombotic complications of vascular surgery, al-resent a type II error as only a relatively small number
though the majority of these studies are retrospec-of patients (22) were judged to have progression of
tive.28,67–69 Ahn retrospectively identified seven patientsPAOD during follow-up.
with aPL who underwent a total of 18 vascular pro-
cedures.70 Three of these patients, none of whom were
anticoagulated developed multiple post-operative
thrombotic complications and all eventually requiredFibrinogen
amputation. The remaining four vascular patients in
this study were taking steroids, anticoagulants, orFibrinogen levels correlate with the severity of PAOD,
vitamin K at the time of the initial operation. A similarhigher levels being associated with more severe dis-
study found that 16 of 19 patients with aPL undergoingease, as determined by claudication distance,25 angio-
a vascular procedure suffered a thrombosis, 12 ofgraphy,55,56 and ABPI.47,49,57 Hyperfibrinogenaemia has
who died.71 In a retrospective report of 234 patientsbeen shown to be predictive for the progression of
undergoing vascular surgery, aPLs were associatedPAOD, as measured by change in claudication dis-
with a shorter bypass patency period (17 vs 58 weeks)tance,51 or the requirement for intervention.50
and a risk of occlusion that was 5.6 times greater thanGiven that hyperfibrinogenaemia is associated with
patients without aPLs.28the development and progression of PAOD, it is un-
The only prospective study to investigate the as-surprising that high levels of fibrinogen are predictive
sociation between aPL and the outcome of vascularof failure of interventions for PAOD.58 Prospective
intervention, showed a trend towards the presence ofstudies have shown that hyperfibrinogenaemia is as-
aPL and failure of arterial bypass surgery, but thissociated with failure of vein and prosthetic femoral
did not reach statistical significance.30 This result ispopliteal bypass grafts.59–62 In addition, associations
unfortunately confounded by the fact that, sig-have been demonstrated between raised fibrinogen
nificantly more of the aPL group were anticoagulatedlevels and graft stenosis, implying that it is not simply
post-operatively thus diminishing any likely differencean increased thrombotic tendency underlying the fail-
ure of such interventions.58,63 Data regarding fibrinogen between the groups.
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Table 1. Patients to be investigated for thrombophilia.Activated protein C resistance/factor V Leiden
1 Venous thromboembolism before the age of 40–45 years
2 Recurrent venous thrombosis or thrombophlebitisOuriel prospectively monitored 76 patients who
3 Thrombosis in an unusual site, e.g. mesenteric vein, cerebralunderwent lower limb revascularisation for a mean of
vein etc.47 months. 60% of those with APC resistance (defined 4 Unexplained neonatal thrombosis
5 Skin necrosis, particularly if on coumarinsas APC ratio <2.0) had an occlusion of their graft, while
6 Arterial thrombosis before the age 30 yearsonly 24% of those without APC resistance suffered a
7 Relatives of patients with thrombophilic abnormalitygraft failure (p<0.02).72 A similar finding was seen in 8 Patients with clear family history of venous thrombosis
9 Unexplained prolonged activated partial thromboplastin timeSampram’s study in which 32% of those with fVL and
10 Patients with recurrent foetal loss, idiopathic49% of those with APC resistance suffered a graft
thrombocytopaenia or SLEocclusion (both p<0.001).41 A study from Foley et al.
reported no association between fVL and graft oc-
clusion, but excluded patients whose graft occluded thrombophilias, in terms of intervention failure and
within six weeks of surgery, a time that others have mortality, reinforce the clinical importance of these
reported as important in graft occlusion associated states in patients with PAOD. The presence of two or
with thrombophilia.35 more co-existent thrombophilias, seems to have an
additive effect, and be particularly dangerous clin-
ically. However, many thrombophilic states may be
asymptomatic for many years and the ‘‘two-hit’’ hypo-
Protein S deficiency thesis suggests that thrombophilic states only become
apparent when a subject is exposed to some other
Although the prevalence of protein S deficiency is thrombogenic trigger such as surgery, oestrogen-con-
higher in patients with PAOD, its significance is un- taining medication, dehydration or systemic upset.
known. Allart investigated the families of young (<45
years old) PAOD patients who were found to be
heterozygotes for protein S deficiency, but no as-
Clinical implicationssociation was found between likelihood of protein
S deficiency, and arterial thrombosis.42 This finding
Screeningcorroborated a previous study, which showed that
relatives of protein S deficient individuals did not have
The British Committee for Standards in Haematologyan increased incidence of arterial thrombosis.73
(BCSH) identified 10 groups of patients who shouldDeficiency of protein S was identified in 4 of 20
be screened for thrombophilia (Table 1).1 The treatmentpatients (20%) whose arterial reconstruction failed
of thrombophilic abnormalities is complex, and thecompared with 6 of 40 (15%) of those with a successful
decision for treatment, which may be lifelong anti-reconstruction at 30 days post surgery, although this
coagulation, should only be made after careful con-difference did not reach statistical significance.42
sideration of the patient, the individual thrombophilia
and any triggering factors that may have precipitated
a previous thrombosis. It is our recommendation that
such patients are referred to a haematologist.Antithrombin III deficiency
In patients with PAOD who do not fall into one of
the groups in Table 1, thrombophilia screening isIn Van der Bom’s population study, examination of
7983 subjects revealed a complex relationship between still likely to reveal an abnormality in approximately
30–60% of patients. In those who are not undergoinglevel of AT III and ABPI.18 In men, mild PAOD was
associated with a high level of ATIII, while severe a vascular intervention, there is no evidence to suggest
that treatment of the thrombophilia will alter the pro-PAOD was associated with lower levels of ATIII. Whilst
in women, there was in an inverse relationship be- gression of arterial disease. There is evidence however,
that patients with a thrombophilia undergoing a vas-tween ABPI and ATIII level. The authors suggest that
levels of ATIII rise in the presence of cardiovascular cular intervention have a poor prognosis, with in-
creased risk of graft occlusion, limb loss and death,disease as a protective mechanism, but as vascular
disease progresses, ATIII becomes consumed, leading and this can be partially offset by treatment. It is
therefore recommended that all patients undergoingto lower levels. The reason for the difference between
the sexes is not clear. a vascular intervention should be screened for a throm-
bophilic tendency.The poor results of intervention in patients with
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Testing for thrombophilia should depend on the and cerebrovascular disease. It seems sensible in the
absence of current evidence however, to lower homo-individual abnormality. Antiphospholipid antibodies,
activated protein C resistance, and hyperhomo- cysteine levels in PAOD patients undergoing inter-
vention.cysteinaemia are the commonest abnormalities, and
should form the basis of a thrombophilia screen.
Screening for protein C and S deficiency, prothrombin
Anti-coagulation20210A, and antithrombin III deficiency may be useful,
Anticoagulation in non-thrombophilic patients is ofbut likely to yield less positive results, although no
benefit in femoro-popliteal bypass grafts when com-less significant.
pared with no treatment, but when compared to as-Assays for homocysteine have previously been dif-
pirin, the data are conflicting.76 The largest study was aficult to perform, due to the requirement for immediate
multicentre, randomised controlled trial investigatingcooling of the sample and separation within 1 h. New
the effectiveness of oral anticoagulation (to maintaintechniques are being developed to improve the sta-
an INR 4.0–4.5) against aspirin (80 mg daily) in 2690bility of blood samples for homocysteine analysis,
patients undergoing infrainguinal bypass surgery,77increasing the ease by which homocysteine assays can
which showed no overall benefit of either treatmentbe performed.74,75
in preventing graft occlusion. Patients with anti-The cost of thrombophilia screening is used as an
phospholipid antibodies who are anticoagulated (withargument against its use. However, if screening were
heparin and subsequently warfarin) when they under-targeted to high-risk groups, such as those in Table 1,
went vascular surgery were noticed to suffer feweror those undergoing intervention, the cost of screening
complications.70 No studies to date have prospectivelymay be offset against the reduced risk of failure of
investigated the use of anticoagulation in PAODvascular intervention. The treatment of intervention
patients with a thrombophilia. However, Khamashitafailure may include prolonged hospital stay, repeated
et al. retrospectively studied the effectiveness of anti-intervention, or amputation, all with significant costs.
coagulation in patients with antiphospholipid syn-A more detailed cost-benefit analysis is beyond the
drome.78 They showed that anticoagulation withscope of this article, and would be difficult to perform
warfarin to an international normalised ratio (INR)given that the lack of trials in this area means the
of >3 was significantly more effective in preventingtrue benefit of screening and/or treatment cannot be
recurrent thrombosis than anticoagulating to an INRquantified.
<3, or aspirin. This study was not confined to patients
with PAOD, but is significant in demonstrating a
benefit of aggressive anticoagulation in thrombophilia.
Treatment
Steroids
Although numerous different treatments are available Whilst the thrombophilias discussed previously are
for thrombophilias, they have not been formally not thought to be associated with a vasculitis, patients
studied in patients with PAOD to determine whether with the lupus anticoagulant who are taking steroids
improved outcomes can be attained. seem to have a reduced thrombotic risk.70 The pro-
tective effect of steroids in conjunction with aspirin
Hyperhomocysteinaemia has been demonstrated previously in obstetric patients,
Patients with hyperhomocysteinaemia, who are under- and leads to a decrease in lupus anticoagulant levels.79
going a vascular intervention, should be treated with There are no data on the use of steroids for PAOD
homocysteine lowering therapy prior to surgery if patients with thrombophilia.
there is sufficient time. If the surgery is urgent, con-
sideration should be given to formally anticoagulating
these patients until the level of homocysteine can be Anti-platelet agents
Aspirin is beneficial in obstetric patients with thereduced. Hyperhomocysteinaemia may be corrected
simply with folic acid, and vitamins B12 and/or B6, lupus anticoagulant.80 The use of aspirin has not been
investigated in PAOD with a thrombophilia, but it isalthough it has yet to be demonstrated whether such
treatment will lead to a reduction in cardiovascular risk suggested that it be used in patients with aPL, with
no history of thrombosis. Patients with aPL undergoingor improvement in patency rates. Trials are presently
being undertaken to determine whether lowering surgery, or with a history of thrombosis should be
formally anticoagulated, as these patients are at highhomocysteine levels is beneficial in terms of outcome
for vascular patients both in PAOD and in cardiac risk of thrombosis.
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